What Does Vyvanse Show Up as on a Drug Test?

Vyvanse (lisdexamfetamine) shows up as amphetamine on a drug test. The drug is a prodrug, meaning your body converts it into d-amphetamine after you swallow it, and d-amphetamine is what accumulates in your blood, urine, saliva, and hair. A standard workplace or clinical urine screen does not distinguish between Vyvanse, Adderall, or illicit amphetamine use, so a positive result simply reads as “amphetamines.” The distinction only becomes possible with more advanced confirmatory testing, which not every testing situation includes automatically.

How Vyvanse Turns Into Amphetamine

Lisdexamfetamine is an inactive molecule on its own. It consists of the amino acid l-lysine bonded to d-amphetamine. After you take a capsule, enzymes in your red blood cells cleave off the lysine, releasing d-amphetamine into your bloodstream. In a pharmacokinetic study of healthy adults, the intact lisdexamfetamine reached its peak blood concentration in about one hour, but the active d-amphetamine did not peak until roughly three hours after the dose.¹ That delayed release is by design and is a big part of why Vyvanse lasts longer than immediate-release amphetamine.

Once the conversion happens, d-amphetamine behaves in your body exactly the way it would if you had taken dextroamphetamine directly. It gets metabolized through the same pathways, produces the same urinary byproducts, and is indistinguishable in a blood draw or urine cup. In the same study, about 42% of the dose was recovered in urine as d-amphetamine, roughly 25% appeared as hippuric acid (a normal metabolic byproduct), and only about 2% came through as intact, unconverted lisdexamfetamine.¹ In other words, almost all of what ends up in your urine is plain amphetamine.

What a Standard Drug Screen Detects

Most workplace, military, and clinical drug tests start with an immunoassay screen. This is the rapid, relatively inexpensive test that checks your urine against a panel of drug categories, usually including amphetamines, opioids, cannabinoids, cocaine, and PCP. The amphetamine immunoassay does not identify the specific amphetamine molecule. It reacts to structural features shared by the whole class, so d-amphetamine, methamphetamine, and their close relatives all trigger the same positive result. If you take Vyvanse as prescribed and are given this type of screen, you will test positive for amphetamines.

One wrinkle worth knowing: not all immunoassay kits are equally sensitive to amphetamine versus methamphetamine. A forensic case report noted that one common immunoassay kit had a detection threshold for amphetamine that was far higher than its threshold for methamphetamine, which means that at low concentrations a simple screening test could theoretically miss amphetamine altogether.² This is unusual and depends on the specific kit, but it underscores that immunoassay results are screening tools, not definitive answers. They catch most cases but are not perfectly calibrated for every amphetamine compound at every dose.

How Confirmatory Testing Can Tell Vyvanse Apart From Street Amphetamine

When a screening test comes back positive, the next step in most regulated testing programs is confirmatory testing using a more precise method, typically liquid chromatography-tandem mass spectrometry (LC-MS/MS). This technology can identify exactly which molecules are present and, crucially, can perform chiral analysis. Chiral analysis separates the “left-handed” and “right-handed” mirror-image forms of amphetamine, known as l-amphetamine and d-amphetamine.

This matters because Vyvanse produces only d-amphetamine (sometimes written as S-amphetamine in scientific literature). Illicit street amphetamine, by contrast, is typically a racemic mixture containing both the d- and l- forms. So if confirmatory testing finds only d-amphetamine in your sample, that is consistent with a prescription for Vyvanse, Adderall, or dextroamphetamine. If both forms appear, it raises questions about whether illicit amphetamine was also used.

A large evaluation of over 24,000 chiral amphetamine test results collected from 2013 to 2023 found that reporting the relative proportion of l-amphetamine alongside total amphetamine concentration was useful for distinguishing ADHD medication adherence from illicit drug use.³ Similarly, a study of hair samples from patients prescribed Vyvanse found only d-amphetamine in eight out of nine patients, while the ninth showed both forms, indicating that person had also used street amphetamine.⁴

There is a small caveat. The body can convert a tiny amount of d-amphetamine into l-amphetamine through normal metabolism. Advanced labs account for this by looking at the ratio rather than requiring a complete absence of l-amphetamine. A trace amount of l-amphetamine alongside a dominant d-amphetamine signal is still consistent with prescription use. A substantial proportion of l-amphetamine is the red flag.

Detection Windows Across Different Test Types

How long Vyvanse remains detectable depends on the specimen type. Since the drug is metabolized to d-amphetamine, the detection window mirrors that of any amphetamine, but the exact timing varies by the testing method.

Urine

Urine is the most common specimen for drug testing. Amphetamine is generally detectable in urine for roughly two to four days after a single therapeutic dose, though this can shift depending on factors covered below. The standard screening cutoff for amphetamines in workplace drug testing is typically 500 or 1,000 ng/mL for the initial immunoassay, with a lower cutoff applied during confirmatory testing. A volunteer study using a single 30 mg dose of lisdexamfetamine found amphetamine detectable in urine at a 50 ng/mL analytical cutoff for a median of about 67 hours after ingestion.⁵ At higher cutoffs used in many workplace programs, the detection window shortens.

Oral Fluid (Saliva)

Oral fluid testing has become more common, especially in roadside testing and some employment settings. In the same volunteer study, amphetamine was detectable in oral fluid for a median of roughly 67 hours after a single 30 mg lisdexamfetamine dose at a 1.5 ng/mL analytical cutoff.⁵ A separate study analyzing oral fluid from patients on Vyvanse therapy found amphetamine concentrations ranging from about 6 to 79 ng/mL, alongside small amounts of intact lisdexamfetamine in some samples.⁶ The presence of intact lisdexamfetamine in saliva, while uncommon, could theoretically help confirm that the person took Vyvanse specifically rather than a different amphetamine formulation.

Oral fluid testing for compliance monitoring in patients prescribed Vyvanse has also shown that chiral analysis works in saliva. One study found that in a group of compliant patients, the median d-amphetamine plus l-amphetamine concentration was around 280 ng/mL, while non-compliant patients who also used illicit amphetamine had a median concentration roughly six times higher.⁷ The concentration difference, combined with the presence of l-amphetamine, gave clinicians a way to identify side use of street amphetamine.

Hair

Hair testing casts the widest net in terms of time, typically covering about 90 days of drug exposure for a standard-length hair sample. D-amphetamine does incorporate into hair after Vyvanse use, and one study confirmed that d-amphetamine was detectable in the hair of all patients taking the medication.⁸ However, the same study found no clear correlation between the prescribed daily dose and the concentration of d-amphetamine in the hair, which makes hair testing useful for confirming exposure but unreliable for gauging how much someone took. Hair testing also supports chiral analysis, so the d-only versus d-plus-l distinction still applies.

Factors That Change How Quickly You Clear Amphetamine

The detection window is not the same for everyone. Several physiological variables push it shorter or longer.

Urine pH

This is one of the biggest variables. Amphetamine is a weak base, and whether it gets reabsorbed by the kidneys or flushed out depends heavily on how acidic or alkaline your urine is. In acidic urine, more than 70% of amphetamine is excreted unchanged, which means it leaves the body faster and produces a stronger signal on a urine test in the short term. In alkaline urine, less than 5% comes out unchanged because the kidneys reabsorb most of it back into the bloodstream.⁹ That is an enormous range. A person with consistently acidic urine might clear amphetamine much faster than someone with alkaline urine, but they will also produce higher urinary concentrations in the hours right after dosing.

Diet, hydration, certain medications, and medical conditions all influence urine pH. A high-protein, meat-heavy diet tends to make urine more acidic, while a vegetarian diet rich in fruits and vegetables tends to push it alkaline. People taking antacids like sodium bicarbonate or the gout drug acetazolamide can have significantly more alkaline urine, potentially prolonging the time amphetamine stays in their system.

Kidney Function

Since amphetamine is primarily cleared through the kidneys, impaired renal function slows elimination. A study comparing people with varying degrees of kidney impairment found that those with severe impairment or end-stage renal disease had roughly a 50% reduction in total body clearance of d-amphetamine compared to people with normal kidney function. Their half-life was also longer, meaning the drug lingered at detectable levels for an extended period.⁹ For someone on dialysis or with chronic kidney disease, this can meaningfully extend the detection window beyond what healthy volunteers experience in studies.

Dose and Duration of Use

A single 30 mg dose produces lower and shorter-lived urinary concentrations than daily dosing at 70 mg over months. With steady daily use, amphetamine accumulates to a higher baseline in the body. After stopping, it takes longer for levels to fall below the test cutoff. Most published detection-window estimates are based on single-dose studies in healthy volunteers, so if you have been taking Vyvanse daily for a long time, expect the real window to be somewhat longer than those numbers suggest.

Other Medications That Trigger False Positives for Amphetamines

If you are not taking Vyvanse or any prescribed amphetamine and still get a positive screen for amphetamines, a surprisingly long list of other medications could be responsible. False positives on immunoassay screens have been reported with antidepressants like bupropion and trazodone, the ADHD drug atomoxetine, the blood-pressure medication labetalol, the diabetes drug metformin, certain antihistamines and decongestants including pseudoephedrine and phenylephrine, and antipsychotics like aripiprazole and chlorpromazine, among others.¹⁰ This is not an exhaustive list. Essentially, any molecule with a structural resemblance to amphetamine can fool an antibody-based screening test.

The fix for a false positive is the same confirmatory testing described earlier. LC-MS/MS can identify the exact molecules present and will not confuse bupropion with amphetamine. If you take any medication on the false-positive risk list and are facing a drug test, disclosing your medications to the medical review officer beforehand saves everyone time and stress. The medical review officer’s job is to interpret results in the context of your prescription history, not to simply report every positive as evidence of abuse.

What to Do When You Have a Legitimate Prescription

A Vyvanse prescription does not exempt you from testing positive. It provides an explanation for the positive result. In regulated testing programs like federal workplace drug testing, the process works like this: you provide your sample, the lab runs the screen, and if it comes back positive for amphetamines, a medical review officer contacts you before any result is reported to your employer. At that point, you disclose your prescription, and the officer verifies it. If confirmed, the result is reported as negative or as consistent with prescribed use, depending on the program.

The key is documentation. Keep a copy of your prescription or pharmacy records accessible. Some people bring a letter from their prescribing physician, though this is not always required. Do not volunteer your prescription information to the specimen collector at the testing site; their role is to handle the sample, not to interpret medical history. Wait for the medical review officer to make contact.

For non-regulated testing, like pre-employment screens run by private companies or tests ordered by a pain clinic, the process is less standardized. Some employers use a medical review officer, while others rely on a third-party lab that may or may not flag the result for review. If you are unsure about the process, ask the testing coordinator ahead of time how prescription medications are handled.

Can a Lab Tell Vyvanse Apart From Adderall?

Not reliably through standard testing. Both Vyvanse and Adderall produce d-amphetamine in the body. Adderall also contains a small proportion of l-amphetamine (it is a mixture of amphetamine salts, about 75% d-amphetamine and 25% l-amphetamine). In theory, a chiral analysis could detect the l-amphetamine from Adderall but not from Vyvanse, giving a clue about which medication was taken. In practice, this distinction is rarely the point of a drug test. Most testing programs care about whether the amphetamine is consistent with any legitimate prescription, not which specific brand you take.

There is one situation where the distinction matters more: forensic toxicology. In autopsy cases and drug-facilitated crime investigations, identifying intact lisdexamfetamine in a specimen can confirm Vyvanse specifically as the source. A forensic case report detected intact lisdexamfetamine in urine at about 31 ng/mL alongside much higher concentrations of d-amphetamine, confirming that the deceased had taken Vyvanse rather than another amphetamine formulation.² But intact lisdexamfetamine is present in such small amounts and is cleared so quickly that finding it requires looking within a narrow time window and using sensitive analytical methods not deployed in routine workplace testing.

Blood Testing and Less Common Specimen Types

Blood (serum or plasma) testing for amphetamines is less common in employment or clinical compliance settings but is standard in emergency medicine and forensic investigations. After a single Vyvanse dose, d-amphetamine reaches peak blood levels at around three hours and then gradually declines. The detection window in blood is shorter than in urine, typically under 24 hours for a single dose at therapeutic levels, though chronic use extends this. Blood tests offer the advantage of reflecting what is actively circulating rather than what has accumulated in urine over time, which makes them better for assessing recent use or current impairment.

Sweat patches and meconium testing (used in newborns) can also detect amphetamine, but these are niche applications. Sweat patches are occasionally used in criminal justice monitoring over periods of one to two weeks. They detect cumulative exposure rather than a single point in time, and amphetamine from Vyvanse would show up just as it would from any other source.

The Prodrug Design and Abuse Deterrence

Vyvanse’s conversion step was intentionally engineered to reduce abuse potential. Because the body has to cleave the lysine off before d-amphetamine becomes active, snorting or injecting lisdexamfetamine does not produce the rapid high associated with immediate-release amphetamine. The drug still gets converted to d-amphetamine eventually, but the rate is limited by the enzymatic step. This prodrug design has no effect on drug test results, though. Whether you take Vyvanse as prescribed, crush and snort it (which would not work well), or take an equivalent dose of plain dextroamphetamine, the urine result is the same: amphetamine positive. The prodrug wrapper is invisible to a drug screen because the screen is looking at the end product, not the starting molecule.

Researchers have noted that very low doses of lisdexamfetamine, well below typical therapeutic amounts, still produce detectable d-amphetamine in hair.⁴ This has raised interest in forensic contexts like drug-facilitated crimes, where even a small covert dose could be traced months later through hair analysis. For the average person taking Vyvanse therapeutically, the takeaway is simpler: there is no dose low enough to fly completely under the radar on a sensitive enough test.